The first participant has been dosed in Vertero Therapeutics’ Phase 1b clinical trial testing VT-5006, an investigational, gut-directed oral small molecule being developed for Parkinson’s disease. The Phase 1b clinical trial (NCT07310264) is still recruiting adults ages 40-80 with early- or moderate-stage…
News
A pivotal clinical trial testing the light therapy device Celeste for Parkinson’s disease has wrapped up, with the last enrolled participant completing the study’s final visit. That’s according to a company press release from device developer Photopharmics, which called the completion of the…
Topline results from a Phase 2 trial testing oral bezisterim as a first-line, stand-alone treatment for early Parkinson’s disease are expected later this year following the completion of the study’s final patient visit. The developer of the therapy, Biovie, announced that researchers…
Researchers at Texas A&M University have identified a protective brain pathway — one linked to receptors responsive to nicotine but not requiring the tobacco plant chemical itself — that may be targeted to slow the progression of Parkinson’s disease. In a mouse model of Parkinson’s, boosting the number of…
Vermont has become the first U.S. state to pass legislation to ban the sale and use of paraquat, an herbicide strongly linked to an increased risk of Parkinson’s disease. With similar bills introduced in a dozen states this year — including New York, Pennsylvania, and Minnesota —…
Cellular Intelligence has acquired global rights from Novo Nordisk to STEM-PD, an allogeneic, or donor-derived, stem cell therapy program for Parkinson’s disease. Under the terms of the agreement, Cellular Intelligence will apply its artificial intelligence (AI) platform to advance the clinical development and manufacturing of the…
Enrollment is now complete in a Phase 3 trial assessing the safety and efficacy of solengepras (CVN424), Cerevance’s experimental non-dopaminergic therapy, in people with Parkinson’s disease. The Phase 3 ARISE trial (NCT06553027) is assessing solengepras’ efficacy, when given with levodopa and other standard Parkinson’s medications, in 341 patients with…
Vyalev, Abbvie‘s continuous under-the-skin infusion formulation of levodopa/carbidopa, reduces off time and eases motor and some nonmotor symptoms in adults with advanced Parkinson’s disease. That’s according to six-month data from an ongoing real-world study, ROSSINI (NCT06107426), which also showed the therapy improves patients’ quality of life. The…
The American Parkinson Disease Association (APDA) has launched a card game, called ParkinSex: The Game, to help people with Parkinson’s disease and their partners overcome challenges with physical and emotional intimacy that may be caused by the condition’s symptoms. The game can be ordered at the organization’s…
Chronic allergic diseases, including asthma and allergic rhinitis (hay fever), may increase the risk of developing Parkinson’s disease by contributing to persistent inflammation in the body, perhaps by maintaining elevated levels of immune cells in circulation, according to a large study from South Korea. While the mechanisms remain unclear,…
Recent Posts
- Guest Voice: Simple bedroom fixes help ensure my husband’s safe sleep
- Study shows Parkinson’s affects brain circuits in different ways
- Blood marker may help detect cognitive decline in Parkinson’s: Study
- ‘Going fishing’ was the response to a discouraging doctor’s appointment
- Parkinson’s forces me to consider what I am passing along